Abstract
Evaluate the status, opportunities and threats for pharmaceutical companies in
Brazil, Russia, India and China now and in the future. Market forecasts to
2013 are provided, plus free quarterly-updated market outlook reports on each
country, keeping you up to date with developments for a full year.
Many are concerned that a potential global economic downturn could blunt
the rapid growth in the BRIC countries. Is this a time of exciting opportunity
or commercial danger for pharmaceutical manufacturers? This report separates
the fact from the fiction and is essential in making sound, impartial business
judgements.
This insightful report provides:
- 5-year forecasts to 2013 and market valuations for each market
- A detailed analysis of the health structure, funding, service and outlook
- Quarterly updated reports of key developments in the market
These leading emerging and rapidly-growing economies represented a total
market of 2.76 billion people and a combined GDP of US$6.1 trillion in 2007.
But where do commercial opportunities exist for pharmaceutical companies now,
and what are the future prospects?
Putting things in perspective
The BRIC countries' pharmaceutical markets are currently valued at US$54.9
billion. This is a large sum of money, but is collectively lower than found in
leading markets such as the USA and Japan. Growth rates, ranging from 5% in
Brazil to 15% in Russia are impressive, but the low starting point - along
with a range of other operational issues - means companies must be targeted in
the opportunities they pursue.
Opportunities do exist
There are, of course, wide regional differences in expenditure levels within
the BRIC countries, far more so than in developed countries where health
systems have evolved to provide a more uniform level of coverage. All four
countries have a relatively wealthy urban population with a far greater
spending power than their respective national average. In the case of China
and India, these urban populations have grown rapidly, and number hundreds of
millions. The challenge for these countries is to extend this level of wealth
to the rest of the population, in order that better levels of healthcare
become affordable.
A long haul
This is evolution not revolution, and change will be incremental. Short-term
opportunities exist in meeting the health demands of the burgeoning middle
classes, and future prospects are bright, where steady growth in BRIC markets
will erode commercial differences with the established markets in North
America, Japan and Europe.
Current and accurate decision support information is vital
Effective planning is vital and that is why Espicom, the leading provider of
pharmaceutical market intelligence, has issued this report collection The
Market for Pharmaceuticals in Brazil, Russia, India & China 2008. For each
country there is a comprehensive examination of the market for pharmaceuticals
which covers all aspects of the operating environment from the regulatory
situation through health provision/expenditure to domestic production.
Importantly, each market evaluation includes 5-year growth forecasts and SWOT
analysis. An additional benefit - at no extra cost - is that concise
quarterly-updated outlook reports are included in the price.
View Cart
